Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa

This study has been completed.

First Received: October 3, 2005 Last Updated: October 11, 2006 History of Changes

Sponsor:	Institute of Child Health
Information provided by:	Institute of Child Health
ClinicalTrials.gov Identifier:	NCT00231517

Purpose

Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa

Condition	Intervention	Phase
Epidermylosis Bullosa	Drug: topical opiod Drug: morphine sulphate in intrasite gel	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: epidermolysis bullosa simplex epidermolysis bullosa with pyloric atresia junctional epidermolysis bullosa

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	4 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

children under 18 years epidermolysis wounds requiring dressing changes

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00231517

Locations

United Kingdom
Great Ormond Street Hospital and the Institute of Child health
London, United Kingdom, WC1N 1EH

Sponsors and Collaborators

Institute of Child Health

Investigators

Principal Investigator:

Richard Howard, Prof

Institute of Child Health

More Information

No publications provided

Study ID Numbers:	01MH17
Study First Received:	October 3, 2005
Last Updated:	October 11, 2006
ClinicalTrials.gov Identifier:	NCT00231517 History of Changes
Health Authority:	United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:

Morphine
Skin Diseases
Skin Diseases, Vesiculobullous
Physiological Effects of Drugs
Skin Abnormalities
Central Nervous System Depressants
Narcotics
Epidermolysis Bullosa
Pharmacologic Actions

Genetic Diseases, Inborn
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Congenital Abnormalities
Central Nervous System Agents
Skin Diseases, Genetic
Analgesics, Opioid

ClinicalTrials.gov processed this record on February 08, 2010